可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Falk E, Shah PK, Fuster V. Coronary plaque disruption[J]. Circulation, 1995, 92(3):657-671.
[2] Dollery CM, McEwan JR, Henney AM. Matrixmetallop roteases and cardiovascular disease[J]. Circ Res, 1995, 77(5):863-868.
[3] Ross R. Atherosclerosisan inflammatory disease[J]. N Engl J Med, 1999, 340(2):115-126.
[4] 许俊堂,胡大一. 对急性冠脉综合征分型的看法[J]. 中华心血管病杂志, 2001, 29(9):566-568.
[5] Suzuki T, Yamazaki T, Yazaki Y, et al. The role of the natriuretic peptidein the cardiovascular system[J]. Cardiovasc Res, 2001, 51(3):489 -494.
[6] Asada J, Tsuji H, Iwasaka T, et al. Usefulness of p lasma brain natriuretic peptide levels in predicting dobutamineinduced myocardial ischemial[J]. Am J Cardiol, 2004, 93(6):702-704.
[7] Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy[J]. Circulation, 2003, 108(3):250-252.
[8] Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction[J]. Circulation, 1993, 88(1):82-91.
[9] de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of Btype natriuretic peptide in patients with acute coronary syndromes[J]. N Engl J Med, 2001, 345(14):1014-1021.
[10]Lu L, Zhang JQ, Ramires FJ, et al. Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue[J]. Biochem Biophys Res Commun, 2004, 320(3):907-913.
[11]庄瑜,陈鑫,石开虎,等. AMI大鼠心肌组织中SDF21与MCP1动态变化及意义[J]. 山东医药, 2007, 47(2):7-10.
[12]de Lemos JA, Morroco DA, Sabatine MS, et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein1 and LongTerm Clinical Outcomes in Patients With Acute Coronary Syndromes[J]. Circulation, 2003, 107(5):690-695.